Compare · WST vs ZIMV
WST vs ZIMV
Side-by-side comparison of West Pharmaceutical Services Inc. (WST) and ZimVie Inc. (ZIMV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both WST and ZIMV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST carries a market cap of $22.59B.
- Over the past year, WST is up 43.0% and ZIMV is up 101.9% - ZIMV leads by 58.9 points.
- WST has hit the wire 4 times in the past 4 weeks while ZIMV has been quiet.
- WST has more recent analyst coverage (16 ratings vs 9 for ZIMV).
- Company
- West Pharmaceutical Services Inc.
- ZimVie Inc.
- Price
- $320.02+1.78%
- $18.99+0.00%
- Market cap
- $22.59B
- -
- 1M return
- -0.60%
- +0.37%
- 1Y return
- +42.97%
- +101.91%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 0
- Recent ratings
- 16
- 9
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
ZimVie Inc.
ZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)
Latest ZIMV
- Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.
- SEC Form 15-12G filed by ZimVie Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by ZimVie Inc.
- Amendment: SEC Form 25-NSE/A filed by ZimVie Inc.
- Officer Kanaglekar Indraneel returned 63,438 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Crawford Sally returned 40,127 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Officer Schneider Sandra returned 40,794 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Asar Vinit K
- Officer Kidwell Heather returned 83,674 shares to the company, closing all direct ownership in the company (SEC Form 4)